Inra Jennifer A, Steyerberg Ewout W, Grover Shilpa, McFarland Ashley, Syngal Sapna, Kastrinos Fay
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Genet Med. 2015 Oct;17(10):815-21. doi: 10.1038/gim.2014.199. Epub 2015 Jan 15.
The aim of this study was to assess whether differences in frequency and phenotype of APC and MUTYH mutations exist among racially/ethnically diverse populations.
We studied 6,169 individuals with a personal and/or family history of colorectal cancer (CRC) and polyps. APC testing involved full sequencing/large rearrangement analysis (FS/LRA); MUTYH involved "panel testing" (for Y165C, G382D mutations) or FS/LRA performed by Myriad Genetics, a commercial laboratory. Subjects were identified as Caucasian, Asian, African American (AA), or other. Statistical tests included χ(2), Fisher's exact test, analysis of variance, and z approximation.
Among participants, 17.5% had pathogenic APC mutations and 4.8% were biallelic MUTYH carriers. With regard to race/ethnicity, 18% were non-Caucasian, with >100 adenomas and younger ages at adenoma or CRC diagnosis (P < 0.0001) than Caucasians. The overall APC mutation rate was higher in Asians, AAs, and others as compared with Caucasians (25.2, 30.9, 24, and 15.5%, respectively; P < 0.0001) but was similar in all groups when adjusted for polyp burden. More MUTYH biallelic carriers were Caucasian or other than Asian or AA (5, 7, 2.7, and 0.3%, respectively; P < 0.0001). Among Caucasians, 5% were biallelic carriers identified by panel testing versus 2% identified by sequencing/large rearrangement analysis (LRA) (P = 0.002). Among non-Caucasians, 3% undergoing panel testing were biallelic carriers versus 10% identified by sequencing/LRA (P < 0.0002).
Non-Caucasians undergo genetic testing at more advanced stages of polyposis and/or are younger at CRC/polyp diagnosis. Restricted MUTYH analysis may miss significant numbers of biallelic carriers, particularly in non-Caucasians.
本研究旨在评估在不同种族/族裔人群中,腺瘤性息肉病(APC)和MutY同源蛋白(MUTYH)基因突变的频率和表型是否存在差异。
我们研究了6169名有结直肠癌(CRC)和息肉个人史及/或家族史的个体。APC检测包括全序列分析/大片段重排分析(FS/LRA);MUTYH检测包括“组套检测”(针对Y165C、G382D突变)或由商业实验室Myriad Genetics进行的FS/LRA。受试者被分为白种人、亚洲人、非裔美国人(AA)或其他种族。统计检验包括卡方检验、Fisher精确检验、方差分析和z近似检验。
在参与者中,17.5%有致病性APC突变,4.8%是MUTYH双等位基因携带者。关于种族/族裔,18%为非白种人,与白种人相比,他们有超过100个腺瘤,且腺瘤或CRC诊断时年龄更小(P < 0.0001)。与白种人相比,亚洲人、非裔美国人及其他种族的总体APC突变率更高(分别为25.2%、30.9%、24%和15.5%;P < 0.0001),但在根据息肉负担进行调整后,所有组的突变率相似。更多的MUTYH双等位基因携带者是白种人或其他种族,而非亚洲人或非裔美国人(分别为5%、7%、2.7%和0.3%;P < 0.0001)。在白种人中,通过组套检测确定的双等位基因携带者为5%,而通过测序/大片段重排分析(LRA)确定的为2%(P = 0.002)。在非白种人中,接受组套检测的3%为双等位基因携带者,而通过测序/LRA确定的为10%(P < 0.0002)。
非白种人在息肉病更晚期阶段接受基因检测,和/或在CRC/息肉诊断时年龄更小。受限的MUTYH分析可能会遗漏大量双等位基因携带者,尤其是在非白种人中。